Guardant Health, Inc collaborates with Amgen
Home » Guardant Health, Inc collaborates with Amgen

GH AMEA on Social MediaGuardant Health, Inc collaborates with Amgen
Guardant Health, Inc collaborates with Amgen
Guardant Health, Inc collaborates with Amgen
LinkedIn

Guardant Health, Inc. and NRG Oncology, a National Cancer Institute (NCI) funded National Clinical Trials Network group conducting clinical and translational research, have initiated the NRG-GI005 study to validate the clinical utility of Guardant Health’s molecular residual disease (MRD) assay as a diagnostic biomarker for selecting which patients with stage II colon cancer need adjuvant chemotherapy.

Open chat
Message us